First-line Platinum-based Chemotherapy and Survival Outcomes in Locally Advanced or Metastatic Pulmonary Lymphoepithelioma-like Carcinoma

Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare and unique subtype of primary non-small cell lung cancer (NSCLC) that histologically resembles undifferentiated nasopharyngeal carcinoma (NPC) [1]. It is recognized to be etiologically associated with Epstein-Barr virus (EBV) infection in endemic area [2]. Currently, pulmonary LELC is classified as “other and unclassified carcinomas” according to the 2015 World Health Organization Classification Lung Tumors [3]. Over the past decades, less than 600 cases have been reported in the literature.

Source: Lung Cancer - September 11, 2019 Category: Cancer & Oncology Authors: Zuan Lin, Sha Fu, Yixin Zhou, Xuanye Zhang, Chen Chen, Li-na He, Haifeng Li, Yuhong Wang, Tao Chen, Li Zhang, Shaodong Hong Source Type: research